Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Rasagiline mesylateCat. No. 4308 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: (1R)-2,3-Dihydro-N-2-propynyl-1H-inden-1-amine methanesulfonate |
Biological Activity
Selective irreversible MAO-B inhibitor. Displays antiParkinsonian activity; exhibits neuroprotective and antiapoptotic activity against several neurotoxins in cell culture.Certificate of Analysis / Safety Data Sheet
References
Finberg and Youdim (2002) Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 43 1110. PMID: 12504917.
Maruyama et al (2002) The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J.Neural Transm. 109 467. PMID: 11956966.
Youdim and Weinstock (2002) Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell.Mol.Neurobiol. 21 555.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Rasagiline mesylate, supplier, Rasagiline, mesylate, monoamine, oxidases, mao-b, mao, b, inhibitors, selective, antiparkinsons, antiparkinsonian
Quick Order
Find multiple products by catalog number
Neurobiology of Parkinson's Disease
Written by A. Schapira
'Neurobiology and Therapeutics of Parkinson's Disease' highlights the neurobiology of Parkinson's disease and summarizes current and novel therapeutic interventions.
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
New Products in this Area
Cyclooxygenase-inhibiting nitric oxide donor
Tocris Events
Win a Kindle
British Cardiovascular Society Annual Conference 2013
June 3 - 5, 2013
London, UK
Booth Number: C54